Prosight Management, LP Eiger Bio Pharmaceuticals, Inc. Transaction History

Prosight Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$8.63 - $12.4 $2.95 Million - $4.23 Million	-341,457 Closed	0 $0
Q3 2018 Nov 15, 2018	SELL	$9.6 - $12.9 $930,864 - $1.25 Million	-96,965 Reduced 22.12%	341,457 $4.1 Million
Q2 2018 Aug 14, 2018	SELL	$8.3 - $16.8 $767,135 - $1.55 Million	-92,426 Reduced 17.41%	438,422 $5.35 Million
Q1 2018 May 14, 2018	SELL	$8.1 - $16.0 $1.2 Million - $2.37 Million	-147,945 Reduced 21.8%	530,848 $5.23 Million
Q4 2017 Feb 13, 2018	BUY	$10.5 - $14.15 $7.13 Million - $9.6 Million	678,793	678,793 $9.47 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.